Redondo J I, Gómez-Villamandos R J, Santisteban J M, Domínguez J M, Ruiz I, Avila I
Department of Animal Medicine and Surgery, Faculty of Veterinary Medicine, University of Cordoba, Spain.
Can J Vet Res. 1999 Jan;63(1):31-6.
The objective of this paper was to evaluate romifidine as a premedicant in dogs prior to propofol-halothane-N2O anesthesia, and to compare it with the other alpha2-agonists (medetomidine and xylazine). For this, ten healthy dogs were anesthetized. Each dog received 3 preanesthetic protocols: atropine (10 microg/kg BW, IM), and as a sedative, romifidine (ROM; 40 microg/kg BW, IM), xylazine (XYL; 1 microg/kg, IM), or medetomidine (MED; 20 microg/kg BW, IM). Induction of anesthesia was delivered with propofol 15 min later and maintained with halothane and N2O for one hour in all cases. The following variables were registered before preanesthesia, 10 min after the administration of preanesthesia, and at 5-minute intervals during maintenance: PR, RR, rectal temperature (RT), MAP, SAP, and DAP. During maintenance, arterial oxygen saturation (SpO2), end-tidal CO2 (EtCO2) and percentage of halothane necessary for maintaining anesthesia (%HAL) were also recorded. Induction dose of propofol (DOSE), time to extubation (TE), time to sternal recumbency (TSR) and time to standing (TS) were also registered. The statistical analysis was carried out during the anesthetic period. ANOVA for repeat measures revealed no differences between the 3 groups for PR and RR; however, MAP, SAP and DAP were higher in the MED group; SpO2 was lower in MED and EtCO2 was lower in ROM; %HAL was higher in XYL. No statistical differences were observed in DOSE, TE, TSR or TS. Percentage of halothane was lower in romifidine and medetomidine than in xylazine premedicated dogs also anesthetized with propofol. All the cardiorespiratory variables measured were within normal limits. The studied combination of romifidine, atropine, propofol, halothane and N2O appears to be a safe and effective drug combination for inducing and maintaining general anesthesia in healthy dogs.
本文的目的是评估罗米非定作为犬在丙泊酚 - 氟烷 - N₂O 麻醉前的一种术前用药,并将其与其他α₂ - 激动剂(美托咪定和赛拉嗪)进行比较。为此,对 10 只健康犬进行麻醉。每只犬接受 3 种麻醉前方案:阿托品(10 μg/kg 体重,肌肉注射),以及作为镇静剂的罗米非定(ROM;40 μg/kg 体重,肌肉注射)、赛拉嗪(XYL;1 μg/kg,肌肉注射)或美托咪定(MED;20 μg/kg 体重,肌肉注射)。15 分钟后用丙泊酚诱导麻醉,所有病例均用氟烷和 N₂O 维持麻醉 1 小时。在麻醉前、麻醉前用药后 10 分钟以及维持期间每隔 5 分钟记录以下变量:心率(PR)、呼吸频率(RR)、直肠温度(RT)、平均动脉压(MAP)、收缩压(SAP)和舒张压(DAP)。在维持期间,还记录动脉血氧饱和度(SpO₂)、呼气末二氧化碳分压(EtCO₂)以及维持麻醉所需的氟烷百分比(%HAL)。记录丙泊酚的诱导剂量(DOSE)、拔管时间(TE)、恢复侧卧姿势时间(TSR)和站立时间(TS)。在麻醉期间进行统计分析。重复测量方差分析显示,3 组之间的 PR 和 RR 无差异;然而,MED 组的 MAP、SAP 和 DAP 较高;MED 组的 SpO₂较低,ROM 组的 EtCO₂较低;XYL 组的%HAL 较高。在 DOSE、TE、TSR 或 TS 方面未观察到统计学差异。在用丙泊酚麻醉的犬中,罗米非定和美托咪定预处理组的氟烷百分比低于赛拉嗪预处理组。所有测量的心肺变量均在正常范围内。所研究的罗米非定、阿托品、丙泊酚、氟烷和 N₂O 的组合似乎是用于健康犬诱导和维持全身麻醉的一种安全有效的药物组合。